Author

Milan Lukas 1

1 Charles University,Prague,Czech Republic

BIOSIMILAR INFLIXIMAB IS EFFECTIVE AND SAFE IN INFLAMMATORY BOWEL DISEASE PATIENTS NAIVE TO ANTI-TNF THERAPY: A TERTIARY CENTER EXPERIENCE

Martin Bortlík, Martin Kolar, Dana Duricova, Karin Malíčková, Veronica Hruba, Nadezda Machkova, Katarina Mitrova, Martin Lukas, Milan Lukas

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

CZECH REGISTRY OF INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGICAL THERAPY: RESULTS FROM THE FIRST YEAR

Martin Bortlík, Premysl Falt, Pavel Drastich, Tomas Douda, Michal Konecny, Vladimir Zboril, Milan Lukas

EFFICACY OF INFLIXIMAB BIOSIMILAR CT-P13 INDUCTION THERAPY ON MUCOSAL HEALING IN ULCERATIVE COLITIS

Tamás Molnár, Renáta Bor, Mariann Rutka, Petra Anna Golovics, Zsuzsanna Vegh, Barbara Dorottya Lovasz, Tibor Nyári, Krisztina Barbara Gecse, Martin Kolar, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronica Hruba, Martin Lukas, Katarina Mitrova, Karin Malíčková, Anita Balint, Ferenc Nagy, Renáta Bor, Ágnes Milassin

ENDOSCOPIC BALLOON DILATION OF STRICTURES IN CROHN´S DISEASE PATIENTS: SAFE AND EFFECTIVE ALTERNATIVE TO REPEATED SURGERY

Martin Bortlík, Dana Duricova, Martin Lukas, Nadezda Machkova, Veronika Hruba, Igor Romanko, Katarina Mitrova, Milan Lukas

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier Gisbert, Geert R. D'Haens, Bu Hayee, Remo Pannacione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber

EXPLORING THE DIVERSITY OF MUTATIONAL LANDSCAPES IN IBD BY TISSUE PROFILING USING A TARGETED NEXT-GENERATION SEQUENCING (NGS) TUMOR PANEL

Petra Minarikova, Lucie Benesova, Barbora Belsanova, Anastasiya Semyakina, Mojmir Kasalicky, Martin Bortlík, Milan Lukas, Miroslav Zavoral, Marek Minarik

FREQUENCY AND CHARACTERISTICS OF INFUSION REACTIONS DURING BIOSIMILAR INFLIXIMAB TREATMENT IN INFLAMMATORY BOWEL DISEASES: RESULTS FROM CENTRAL EUROPEAN NATIONWIDE COHORT

Anita Balint, Mariann Rutka, Zsuzsanna Vegh, Zsuzsanna Kürti, Krisztina Barbara Gecse, János Banai, László Bene, Beata Gasztonyi, Tünde Kristóf, László Lakatos, Pal Miheller, Karoly Palatka, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze, Renáta Bor, Ágnes Milassi

IMPACT OF ANTI-TNFΑ THERAPY FOR MATERNAL INFLAMMATORY BOWEL DISEASE DURING PREGNANCY ON IMMUNE SYSTEM OF EXPOSED CHILDREN

Dana Duricova, Nadezda Machkova, Martin Bortlík, Jana Kozeluhova, Pavel Kohout, Ludek Hrdlicka, Marianna Durilova, Katarina Mitrova, Ondrej Hradsky, Jiri Bronsky, Milan Lukas

Impact of the switch from original adalimumab to biosimilar adalimumab SB5 on serum drug trough levels, clinical and biological disease activity in patients with IBD

Milan Lukas, Veronika Pešinová, Martin Bortlík, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Martin Vašátko, Karin Malíčková

Item 1 - 10 / 33
1
2 3 4